BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 16, 2020
View Archived Issues
FDA clears IND for phase I/IIa study of V2ACT for pancreatic cancer
Read More
Graphite Bio allowed to initiate phase I/II CEDAR study of GPH-101 in sickle cell disease
Read More
Updated results from phase I/II study of FLT-180a in hemophilia B
Read More
Paying attention to the little guy in proteomics
Read More
Gene therapy in one eye improves vision in both
Read More
Codagenix announces the initiation of first in human study of COVI-VAC in the U.K.
Read More
Cancer Research UK approves Teon's TT-702 for clinical collaboration
Read More
Ashvattha collaborates with Stanford on preclinical study of OP-801 imaging of neuroinflammation
Read More
Positive interim data presented from phase IIb portion of ifenprodil COVID Study
Read More
First phase III study of dasiglucagon in congenital hyperinsulinism does not meet primary endpoint
Read More
Verastem initiates phase II registration-directed study of VS-6766 plus defactinib in NSCLC
Read More
Lantern announces promising preclinical data for LP-184 in GBM
Read More
Positive phase II data for PL-9643 in patients with moderate to severe dry eye disease
Read More
Initiation of first-in-human study of CVB vaccine candidate, PRV-101
Read More
Phase I results show safety and activity with rintodestrant in ER+/HER2- breast cancer
Read More
Voronoi discloses new RET inhibitors
Read More
First patients enrolled in phase IIb study of rNAPc2 for COVID-19
Read More
Merck & Co. patents NPR1 agonists
Read More
Medshine Discovery identifies new RIP-1 inhibitors
Read More
Merck & Co. discovers new compounds for HIV infection
Read More
SMAD3 as new therapeutic target for NSCLC
Read More
Duke University presents new pro-N-cadherin-targeting humanized antibodies
Read More
PRDM2, a novel SMAD3-dependent immunosuppressor for promoting NSCLC
Read More
Phase IIb/III study of oral masitinib in Alzheimer's disease meets primary endpoint
Read More
Low-dose cohort data reported from phase I/II study of AXO-AAV-GM1 for GM1 gangliosidosis
Read More
Glutamate "plumes" identified in spreading depression, migraine
Read More
Valneva opens phase I/II study of COVID-19 vaccine candidate VLA-2001
Read More
Clinical benefit seen with SOR-007 in patients with cutaneous metastases
Read More
Nascent cleared by FDA to begin phase I trial of pritumumab for brain cancer
Read More
Kineta initiates phase I trial of KCP-506 for chronic neuropathic pain
Read More